<DOC>
	<DOCNO>NCT02678780</DOCNO>
	<brief_summary>This prospective , international , multi-center , open label , stratify , exploratory phase II study evaluate efficacy safety lenvatinib patient advanced/metastatic , neuroendocrine tumor pancreas progression previous target agent ( cohort A ) gastrointestinal tract progression somatostatin analogue ( cohort B ) .</brief_summary>
	<brief_title>Lenvatinib Efficacy Metastatic Neuroendocrine Tumors</brief_title>
	<detailed_description>Trial ass efficacy Lenvatinib metastatic neuroendocrine tumor . The primary endpoint study overall response rate ( ORR ) RECIST v 1.1 upon central radiologic assessment . Number patient : 110 patient Estimated duration subject participation : 24 month</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>INCLUSION CRITERIA Subjects must meet follow criterion include study : 1 . Subjects must histologically confirm diagnosis one follow advanced/metastatic neuroendocrine tumor type : 1. WHO Classification G1/G2 ( Ki67 &lt; 20 % mitotic count ≤20 mitoses x 10 HPF ) pancreatic neuroendocrine tumor 2. WHO Classification G1/G2 ( Ki67 &lt; 20 % mitotic count ≤20 mitoses x 10 HPF ) gastrointestinal neuroendocrine tumor ( include stomach , small intestine colorectal origin ) . 2 . Subjects must evidence measurable disease meeting follow criterion : 1 . At least 1 lesion ≥ 1.0 cm long diameter nonlymph node , ≥ 1.5 cm shortaxis diameter lymph node , serially measurable accord RECIST 1.1 ( Appendix I ) use computerize tomography/magnetic resonance imaging ( CT/MRI ) . If one target lesion nonlymph node , long diameter ≥ 1.5 cm . 2 . Lesions external beam radiotherapy ( EBRT ) locoregional therapy radiofrequency ( RF ) ablation liver embolization must show evidence progressive disease base RECIST 1.1 deem target lesion . 3 . Subjects must show evidence disease progression radiologic image technique within 12 month ( additional month allow accommodate actual date performance scan , i.e. , within ≤ 13 month ) prior sign inform consent , accord RECIST 1.1 ( Appendix I ) . 4 . Subjects must meet following inclusion criterion regard primary tumor site : 1 . Pancreatic origin : progression previous target agent ( include mTOR inhibitor , everolimus antiangiogenic therapy , sunitinib , sorafenib , axitinib , bevacizumab within others ) . Combination therapies treatment line ( sorafenib plus bevacizumab , chemotherapy plus antiangiogenic drug ) consider one treatment line allow include study . Patients must treat one previous line target agent ( ) base therapy . Previous therapy somatostatin analogue and/or interferon allow consider previous target agent therapy . 2 . Gastrointestinal origin : progression therapy antitumoral dos somatostatin analog ( octreotide LAR 30 mg every 28 day Lanreotide 120 mg every 28 day ) and/or interferon treatment . 5 . Only patient pancreatic origin neuroendocrine tumor , one previous line chemotherapy allow . 6 . Concomitant somatostatin analogue allow cohort study . 7 . Patients know brain metastasis complete whole brain radiotherapy , stereotactic radiosurgery complete surgical resection , eligible remain clinically stable , asymptomatic steroid least one month . 8 . All prior chemotherapy radiationrelated toxicity must resolve &lt; Grade 2 ( follow CTCAE V 4.03 grade level ) , except alopecia infertility . 9 . Subjects must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 − 1 ( Appendix II ) . 10 . Previous liver locoregional therapy , ( chemo ) embolization , radiofrequency liverdirected radioembolization , systemic peptidereceptor radionucleotide therapy allow procedure perform least 6 month previous informed consent form signature . 11 . Adequately control blood pressure without antihypertensive medication , define BP &lt; 150/90 mmHg screen change antihypertensive medication within 1 week prior Screening Visit . 12 . Adequate renal function define calculated creatinine clearance ≥ 30 mL/min per Cockcroft Gault formula ( Appendix III ) 13 . Adequate bone marrow function , define : 1 . Absolute neutrophil count ( ANC ) ≥ 1500/mm3 ( ≥ 1.5 × 103/μL ) . 2 . Platelets ≥ 100,000/mm3 ( ≥ 100 × 109/L ) . 3 . Hemoglobin ≥ 9.0 g/dL . 14 . Adequate blood coagulation function evidence International Normalized Ratio ( INR ) ≤ 1.5 . Prophylactic low molecular weight heparin therapy allow . 15 . Adequate liver function : 1 . Bilirubin ≤ 1.5 × upper limit normal ( ULN ) except unconjugated hyperbilirubinemia Gilbert 's syndrome . 2 . Alkalin phosphatase , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤ 3 × ULN ( ≤ 5 × ULN subject liver metastasis ) . 16 . Males females age ≥ 18 year time inform consent . 17 . All female must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit beta human chorionic gonadotropin ( β hCG ) baseline visit ( and/or within 72h prior first dose study drug ) . Females childbearing potential must agree use highly effective method contraception ( e.g. , total sexual abstinence* , intrauterine device , doublebarrier method condom + spermicide condom + diaphragm spermicide vasectomize partner confirm azoospermia ) throughout entire study period 30 day study drug administration . The subject exempt requirement postmenopausal woman ( defined woman amenorrheic least 12 consecutive month , appropriate age group , without know suspected primary cause ) subject sterilize surgically otherwise prove sterile ( i.e. , bilateral tubal ligation surgery least 1 month prior dose , hysterectomy , bilateral oophorectomy surgery least 1 month prior dose ) . The woman use oral hormonal contraceptive add additional barrier method unknown whether lenvatinib may reduce effectiveness hormonal contraceptive . All woman reproductive potential use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week prior 30 day study drug discontinuation . * Sexual abstinence acceptable line prefer usual lifestyle subject . 18 . Male subject partner woman childbearing potential must use partner must use highly effective method contraception ( e.g. , condom + spermicide , condom + diaphragm spermicide , IUD ) begin least 1 menstrual cycle prior start study drug ( ) , throughout entire study period , 30 day last dose study drug , unless sexually abstinent undergone successful vasectomy . Those partner use hormonal contraceptive must also use additional approve method contraception , describe previously . 19 . Voluntary provision write informed consent willingness ability comply aspects protocol . EXCLUSION CRITERIA Subjects meet follow criterion exclude study : 1. WHO Classification G3 neuroendocrine tumor pancreas gastrointestinal tract . 2 . Two prior line target agentsbased therapy pancreatic origin previous line target therapy gastrointestinal origin ongoing antiproliferative treatment advanced/metastatic neuroendocrine tumor , exception somatostatin analogue therapy . 3 . More one previous line chemotherapy pancreatic neuroendocrine tumor . 4 . Previous chemotherapy gastrointestinal neuroendocrine tumor . 5 . Prior treatment lenvatinib . 6 . Subjects receive anticancer treatment within 21 day investigational agent within 30 day prior first dose study drug recover toxicity relate previous anticancer treatment . This apply use somatostatin analogue symptomatic therapy . 7 . Major surgery within 3 week prior first dose study drug . 8 . Subjects &gt; 1+ proteinuria urine dipstick test undergo 24h urine collection quantitative assessment proteinuria . Subjects urine protein ≥ 1 g/24h ineligible . 9 . Gastrointestinal malabsorption , condition opinion investigator might affect absorption lenvatinib . 10 . Significant cardiovascular impairment : history congestive heart failure great New York Heart Association ( NYHA ) Class II , unstable angina ; myocardial infarction stroke within 6 month prior first dose study drug , cardiac arrhythmia require medical treatment . The left ventricular ejection fraction echocardiogram must least 50 % . 11 . Prolongation QTcF interval &gt; 480 msec . 12 . Bleeding thrombotic disorder use anticoagulant , warfarin , similar agent require therapeutic international normalize ration ( INR ) monitoring . Treatment low molecular weight heparin ( LMWH ) allow . 13 . Active hemoptysis ( bright red blood least 0.5 teaspoon ) within 3 week prior first dose study drug . 14 . Active infection ( infection require treatment ) . 15 . Active malignancy within past 5 year ( except melanoma insitu , basal squamous cell carcinoma skin , carcinoma insitu cervix ) . 16 . Known intolerance hypersensitivity active substance ( excipients ) . 17 . Any medical condition , opinion investigator , would preclude participation clinical trial . 18 . Females pregnant breastfeeding . 19 . Documented active alcohol drug abuse . 20 . Patients prior history noncompliance medical regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>